From 2027, Indian generics companies and Hetero Labs Dr. Reddy's will supply lenacapavir, a twice-yearly injectable PrEP with ~96-100% efficacy, for US$40 (R698) per person per year across 120 low- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback